RAD51B and prostate cancer: Six of the NGS-predicted deletions > 1 Kb result in exon loss within genes of known oncogenic potential, including a 59 Kb deletion in the prostate cancer risk associated DNA repair gene RAD51B [28], a 209 Kb deletion in the tyrosine kinase receptor gene ROR2 shown to be depleted in metastatic prostate cancer [29] and a 826 Kb deletion of the androgen receptor corepressor gene SMAD1 [30].